Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer’s Disease
A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSCs) Infusion Versus Placebo in Patients With Alzheimer’s Disease
Researchers at hospitals in CA and FL seek patients with Alzheimer’s Disease to trial a treatment of donated (allogeneic) mesenchymal stem cells or placebo to test the treatments’ ability to reduce their symptoms over the next year.
- Be 50 years to 80 years of age
- Have a body mass of 45 – 150 kg
- Not have any other neurodegenerative disease
THE STUDY INVOLVES:
- Prescreening at the study site to confirm eligibility of the patient to participate
- Infusion of the allogeneic stem cells
- Lab and psychological assessments will continue at Baseline, 2, 4, 13, 26, 39, and 52 weeks
LOCATIONS AND CONTACTS:
The following locations are participating in the study:
United States, California
UCLA School of Medicine in Los Angeles, CA. Map.
Brain Matters Research in Delray Beach, FL. Map.
University of Miami Miller School of Medicine in Miami, FL. Map.
Miami Jewish Health in Miami, FL. Map.
Contact: Suzanne L Page | 305-909-0850 | [email protected]
Contact: Amy Drouillard | 305-909-0840 | [email protected]
Or go online: